Potential role for antiangiogenic proteins in the myocardial infarction repair process

Jess L Thompson1, James A Ryan, Mark L Barr

  • 1Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Insights

Endothelial-monocyte activating polypeptide II (EMAP II), an antiangiogenic protein, is upregulated after myocardial infarction. Its changing distribution suggests a role for negative vascular modulators in heart repair.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Tissue Repair Mechanisms

Background:

  • Angiogenic proteins promote revascularization after myocardial infarction (MI).
  • The role of antiangiogenic proteins in cardiac repair post-MI is largely unknown.
  • Endothelial-monocyte activating polypeptide II (EMAP II) is an antiangiogenic protein.

Purpose of the Study:

  • To investigate the temporospatial distribution of EMAP II in a rat model of MI.
  • To determine if antiangiogenic proteins play a role in myocardial repair following infarction.

Main Methods:

  • Utilized a rat model of myocardial infarction.
  • Examined EMAP II distribution via in situ hybridization.
  • Assessed EMAP II protein expression using Western analysis over 6 weeks.

Main Results:

  • EMAP II expression and mRNA increased significantly post-MI, localizing to the infarct region and inflammatory cells.
  • EMAP II protein remained elevated for 6 weeks, with transcription shifting to fibroblasts in scar tissue.
  • EMAP II distribution changed from perivascular stroma in normal myocardium to inflammatory cells and then fibroblasts post-MI.

Conclusions:

  • The temporospatial dynamics of EMAP II suggest a role for antiangiogenic proteins in myocardial revascularization.
  • Negative vascular modulators may be involved in the repair process after acute myocardial infarction.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...